Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC590 for Postsurgical Pain Following Inguinal Hernia Repair
NCT05161637Phase 3Not yet recruiting
- Sponsor
- Taiwan Liposome Company
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 3, randomised, double-blind trial of TLC590 in Persistent postsurgical pain (PPSP) (5 arms), sponsored by Taiwan Liposome Company. Primary endpoints: Area Under the Curve of Numerical Pain Rating Scale with Movement 0-24 hours and Area Under the Curve of Numerical Pain Rating Scale with Movement 0-72 hours. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
TLC590
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT05161637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161637.